MRI safety update 2008: Part 1, MRI contrast agents and nephrogenic systemic fibrosis

American Journal of Roentgenology

Volumn 191, Issue 4, 2008, Pages 1129-1139

  Shellock, Frank G ^a   Spinazzi, Alberto ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Bracco Research USA   (United States)

Author keywords

3 T MRI; Devices; Gadolinium based contrast agents; Implants; MRI artifacts; MRI contrast agents; MRI safety; Nephrogenic systemic fibrosis

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CHLORDANE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; PROCOLLAGEN;

ACUTE KIDNEY FAILURE; DIAGNOSTIC PROCEDURE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY FIBROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SAFETY;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; SKIN DISEASES;

EID: 53249135019     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.08.1038.1     Document Type: Review

References (130)

1. Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology 2004; 232:635-652
2. Shellock FG. Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system. J Magn Reson Imaging 2002; 16:721-732
3. Schenck JF. Safety of strong, static magnetic fields. J Magn Reson Imaging 2000; 12:2-19
4. Schaefer DJ, Bourland JD, Nyenhuis JA. Review of patient safety in time-varying gradient fields. J Magn Reson Imaging 2000; 12:20-29
5. Shellock FG. Radiofrequency energy-induced heating during MR procedures: a review. J Magn Reson Imaging 2000; 12:30-36
6. McJury M, Shellock FG. Auditory noise associated with MR procedures: a review. J Magn Reson Imaging 2000; 12:37-45
7. Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. J Magn Reson Imaging 1991; 1:97-101
8. Kanal E, Shellock FG. Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. J Magn Reson Imaging 1992; 2:247-248
9. Shellock FG, Kanal E. Guidelines and recommendations for MR imaging safety and patient management. III. Questionnaire for screening patients before MR procedures. The SMRI Safety Committee. J Magn Reson Imaging 1994; 4:749-751
10. Wood TO. MRI safety. In: Akay M, ed. Wiley encyclopedia of biomedical engineering. Hoboken, NJ: Wiley, 2006:2360-2371
11. Shellock FG. Chapter 24: magnetic resonance bioeffects, safety, and patient management. In: Edelman R, Hesselink J, Zlatkin M, Crues JV, eds. Clinical magnetic resonance imaging, 3rd ed. Philadelphia, PA: Saunders, 2005
12. Shellock FG. Reference manual for magnetic resonance safety, implants, and devices: 2008 edition. Los Angeles, CA: Biomedical Research Publishing Group, 2008
13. Shellock FG. Magnetic resonance procedure: health effects and safety. Boca Raton, FL: CRC Press, 2001
14. Shellock FG. MRIsafety.com: MRI safety, bioeffects and patient management. www.mrisafety.com. Published 2001. Updated 2008. Accessed June 25, 2008
15. Website for the Institute for Magnetic Resonance Safety, Education, and Research. www.IMRSER.org. Published 2001-2004. Updated 2008. Accessed June 25, 2008
16. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356:1000-1001
17. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006; 8:151-157
18. DeHoratius D, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006; 19:191-194
19. Introcaso CE, Hivnor C, Cowper S, Werth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 2007; 46:447-452
20. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238-249
21. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130:209-212
22. Keyrouz S, Rudnicki SA. Neuromuscular involvement in nephrogenic systemic fibrosis. J Clin Neuromusc Dis 2007; 9:297-302
23. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139:903-909
24. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008; 21:123-128; DOI:10.1111/j.1525-139X.2007. 00399.x
25. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785-790
26. Cowper SE, Su L, Robin H, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383-393
27. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 2008; 5:36-39
28. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66:191-199; DOI: 10.1016/j.ejrad.2008.01.016
29. Cowper SE. Nephrogenic systemic fibrosis. NFD/NSF Website: 2001-2008. www.icnfdr.org. Updated January 20, 2008. Accessed March 10, 2008
30. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006; 21:1307-1311
31. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003; 143:678-681
32. Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006; 7:237-247
33. Kanal E, Barkovich AJ, Bell C, et al.; ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR 2007; 188:1447-1474
34. Thomsen HS; European Society of Urogenital Radiology. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007; 17:2692-2696
35. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007; 7:130-137
36. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108 [Erratum in Nephrol Dial Transplant 2006; 21:1745]
37. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362
38. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22:3174-3178
39. Nowack R, Wachtler P. Scleroderma-like syndrome triggered by gadolinium. Nephrol Dial Transplant 2006; 21:3344
40. Boyd AS, Zic JA, Abraham JK. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30
41. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26
42. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157
43. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188:586-592
44. Khurana A, Runge V, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42:139-145
45. Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2007; 22:1395
46. Cheng S, Abramova L, Saab G, et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium containing contrast agents: St. Louis, Missouri, 2002-2006. Morb Mortal Wkly Rep 2007; 56:137-141
47. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2:264-267
48. Pryor JG, Scott GA. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007; 57:105-111
49. Pryor JG, Scott GA. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. (letter to the editor) J Am Acad Dermatol 2007; 57:902-903
50. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2:258-263
51. Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007; 32:353-358
52. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245:168-175
53. Cheung PPM, Dorai Raj AK. Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis. (reply to a letter) Int Med J 2007; 37:509
54. Cheung PPM, Dorai Raj AK. Nephrogenic fibrosing dermopathy: a new clinical entity mimicking scleroderma. Int Med J 2007; 37:139-141
55. Moreno Romero JA, Segura S, Mascaró JM, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007; 157:783-787
56. Garovic VD, Helgen KE. Images in clinical medicine: nephrogenic fibrosing dermopathy. N Engl J Med 2007; 357:e2
57. Hamilton-Persaud K, Ezell LD, Macklin JG. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nephrol Nurs J 2007; 34:283-287
58. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007; 143:1025-1030 [Erratum in Arch Dermatol 2007; 143:1565]
59. Morris MF, MacGregor J, Zhang H, et al. Factors relating to development of nephrogenic systemic fibrosis following gadolinium. Proc Int Soc Magn Reson Med 2007; 15:739
60. Salman KN, Moreira R, Sharma P, Tudorascu D, Holder C, Martin DR. Evaluation of a possible risk association between nephrogenic sclerosing dermopathy (NFD) and gadolinium-enhanced MRI. Proc Int Soc Magn Reson Med 2007; 15:742
61. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007; 2:199-205
62. Plamondon I, Samson C, Watters AK, et al. Nephrogenic systemic fibrosis: more hard times for renal failure patients [in French]. Nephrol Ther 2007; 3:152-156
63. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22:3179-3185
64. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433-3441
65. Pieringer H, Schmekal B, Janko O, Biesenbach G. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22:3094
66. Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis. Pediatr Dev Pathol 2007; 10:395-402
67. Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol 2007; 41:565-566
68. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007; 26:1198-1203
69. Martin DR. Nephrogenic systemic fibrosis. Pediatr Radiol 2008; 38[suppl 1]:S125-S129
70. Clorius S, Technau K, Watter T, et al. Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent. Clin Nephrol 2007; 68:249-252
71. Tsai CW, Chao CC, Wu VC, Hsiao CH, Chen YM. Nephrogenic fibrosing dermopathy in a peritoneal dialysis patient. Kidney Int 2007; 72:1294
72. Saussereau E, Lacroix C, Cattaneo A, Mahieu L, Goulle JP. Hair and fingernail gadolinium ICPMS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 2007; 176:54-57
73. Weenig RH, Gibson LE, el-Azhary R. The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. Semin Cutan Med Surg 2007; 26:163-167
74. Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008; 158:607-610
75. Naylor E, Hu S, Robinson-Bostom L. Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. J Am Acad Dermatol 2008; 58:149-150
76. Caccetta T, Chan JJ. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium. Australas J Dermatol 2008; 49:48-51
77. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43:141-144
78. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747-751
79. Kane GC, Stanson AW, Kalnicka D, et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. Nephrol Dial Transplant 2008; 23:1233-1240
80. Dhungel A, Lattupalli R, Topf J. Nephrogenic fibrosing dermopathy. Scientific World Journal 2008; 8:164-165
81. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR 2008; 190:736-741
82. Prasad SR, Jagirdar J. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists. J Comput Assist Tomogr 2008; 32:1-3
83. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008; 246:11-14
84. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22:3179-3185
85. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
86. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614-617
87. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: setting the record straight. Semin Arthritis Rheum 2006; 35:208-210
88. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of Gd-BOPTA in subjects with renal impairment. Invest Radiol 1999; 34:443-448
89. Yoshikawa K, Davies A. Safety of ProHance in special populations. Eur Radiol 1997; 7[suppl 5]:S246-S250
90. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodynamics or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5:491-502
91. Schuhmann Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975-979
92. Chachuat A, Molinier P, Bonnemain B, Chambon C, Gayet JL. Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure. Eur Radiol 1992; 2:326-329
93. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999; 9:317-321
94. Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000; 35:35-40
95. Krahe T, Götz R, Lackner K, et al. Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis [in German]. Rofo 1992; 156:523-526
96. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:710-712
97. Tweedle MF. Physiochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992; 27[suppl 1]:S2-S6
98. Idee JM, Port C, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20:563-576
99. Lorusso V, Pascolo L, Fernetti C, Anelli PL, Uggeri F, Tiribelli C. Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Des 2005; 11:4079-4098
100. Caravan P, Comuzzi C, Crooks W, McMurry TJ, Choppin GR, Woulfe SR. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 2001; 40:2170-2176
101. Tweedle MF. "Stability" of gadolinium chelates. Br J Radiol 2007; 80:583-584
102. Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 2008; 5:29-35
103. Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21:135-139; DOI: 10.1111/j.1525-139X.2007.00406.x
104. Thomsen HS. Nephrogenic systemic fibrosis. Imaging Decis MRI 2008; 11:13-18
105. Ozaki M, Kawabata T, Awai M. Iron release from haemosiderin and production of iron-catalysed hydroxyl radicals in vitro. Biochem J 1988; 250:589-595
106. Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 1986; 36:466-472
107. Mann JS. Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 1993; 17[suppl 1]:S19-S23
108. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43:65-75
109. Anavekar NS, Chong AH, Norris R, Dowling J, Goodman D. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. Australas J Dermatol 2008; 49:44-47
110. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7:1-8
111. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent "activates" fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214:584-593 [Erratum in J Pathol 2008 aPr; 214:593]
112. Aime S, Canavese C, Stratta P. Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate. Kidney Int 2007; 72:1162-1163
113. Joy MS, Finn WF; LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42:96-107
114. De Broe M. Can the risk of gadolinium be extrapolated to lanthanum? Semin Dial 2008; 21:142-144; DOI:10.1111/j.1525-139X.2007.00416.x
115. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004; 39:138-142
116. Jaar BG, Khatib R, Plantinga L, Boulware LE, Powe NR. Principles of screening for chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:601-609
117. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470
118. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
119. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147 [Erratum in Ann Intern Med 2003; 139:605]
120. Stevens LA, Manzi J, Levey AS, et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis 2007; 50:21-35
121. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53:766-772
122. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254
123. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259-263
124. European Medicines Agency. European public assessment report: increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. London, UK: EMEA, June 26, 2007
125. European Medicines Agency Website. OptiMARK: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/optimark/optimark.htm. Published February 8, 2007. Accessed March 5, 2008
126. Safety Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan. Notification no. 0427001. Published April 27, 2007. Updated October 31, 2007
127. U.S. Food and Drug Administration Website. Information on gadolinium-containing contrast agents. Updated May 23, 2007. www.fda.gov/cder/drug/infopage/GBCA/default.htm. Accessed March 10, 2008
128. NSF information sheet for physicians. Department of Radiology, University of Wisconsin, Madison, WI, Website. www.radiology.wisc.edu/fileShelf/ forReferring/NSF_infoSheet_for-Physicians.pdf. Accessed March 2008
129. Kay J. What causes nephrogenic systemic fibrosis? The Rheumatologist 2007; 9:18-20
130. Thomsen HS. Nephrogenic systemic fibrosis. Imaging Decisions 2008; 11:13-18